Table: Takeda Pharmaceutical Company Limited -6-MTH group results (IFRS)

Takeda Pharmaceutical

29/10/2026 06:30

29 Oct 2026 06:30:13

 Oct 29 (Reuters)-
Takeda Pharmaceutical Company Limited
 CONSOLIDATED FINANCIAL HIGHLIGHTS

 (in billions of yen unless specified)

               6 months ended  6 months ended    Year to
              Sep 30, 2026    Sep 30, 2025   Mar 31, 2027
                 LATEST         YEAR-AGO        LATEST
                RESULTS         RESULTS        FORECAST
Sales          2.41 trln       2.22 trln      4.70 trln
               (+8.4 pct)      (-6.9 pct)     (+4.3 pct)
Operating        406.74          253.56         453.00
              (+60.4 pct)     (-27.7 pct)
Pretax           318.69          178.80         270.00
              (+78.2 pct)     (-30.1 pct)
Net              305.63          112.44         209.00
              (+171.8 pct)    (-40.0 pct)
EPS Basic      192.53 yen      71.57 yen      131.28 yen
EPS Diluted    189.52 yen      70.45 yen          --
Ann Div            --          200.00 yen     204.00 yen
-Q2 div        102.00 yen      100.00 yen         --
-Q4 div            --          100.00 yen     102.00 yen


 NOTE - Takeda Pharmaceutical Company Limited.
(Figures are reported based on international accounting rules (IFRS).)

If there is no Q1 or Q3 dividend, Q2 will in most cases correspond to the first-half
dividend and Q4 to the second-half dividend announced before a new corporate law in
 2006 allowed companies to pay and report dividends on a quarterly basis.
  *Net - represents Net profit attributable to owners of the parent company.
 To see Company Overview page, click reuters://REALTIME/verb=CompanyData/ric=4502.T